Indications
Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD): It is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Treatment of Thrombocytopenia in Patients with Chronic Immune Thrombocytopenia (ITP): It is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Dosage And Administration
Recommended Dosage for Patients with Chronic Liver Disease: Recommended Dose and Duration in Patients with Chronic Liver Disease Scheduled to Undergo a Procedure-
Platelet count less than 40X109/L: 60 mg (3 tablets) for 5 days
Platelet count 40 to less than 50X109/L: 40 mg (2 tablets) for 5 days
Recommended Dosage for Patients with Chronic Immune Thrombocytopenia: Initial Dose Regimen: Begin Avatrombopag at a starting dose of 20mg (1tablet) once daily with food. Avatrombopag Dose Adjustments for Patients with Chronic Immune Thrombocytopenia-
Less than 50 after at least 2 weeks of Avatrombopag x 109/L: Increase One Dose Level. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.
Between 200 and 400 x 109/L: Decrease One Dose Level. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.
Greater than 400 x 109/L: Stop Avatrombopag. Increase platelet monitoring to twice weekly. When platelet count is less than 150 x10 9 /L, decrease One Dose Level per Table 3 and reinitiate therapy.
Less than 50 after 4 weeks of Avatrombopag 40 mg once daily x 109/L: Discontinue Avatrombopag.
Greater than 400 after 2 weeks of Avatrombopag 20 mg weekly x 109/L: Discontinue Avatrombopag.
Or, as directed by the registered physician.
Side Effects
In patients with chronic liver disease, the most common adverse reactions were pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral. In patients with chronic immune thrombocytopenia, the most common adverse reactions were headache, fatigue, confusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.
Precautions And Warnings
Thrombotic/Thromboembolic Complications : Avatrombopag is a thrombopoietin (TPO) receptor agonist and
TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Monitor platelet counts and for thromboembolic events and institute treatment promptly.
Pregnancy And Lactation
Pregnant women should be advised of the potential risk to a fetus. Females of reproductive potential should be advised to inform their prescriber of a known or suspected pregnancy. Women should be advised not to breastfeed during treatment with Avatrombopag and for at least 2 weeks after the final dose.